The following is a listing from SAA of active third party spondylitis research opportunities. SAA is not affiliated with these studies, and is sharing them as a service to the community.
A phase 4 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate in a study evaluating the clinical difference between 300 mg and 150 mg of secukinumab.
The purpose of the trial, titled, “Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)” is to investigate the effectiveness, impact, and performance of different secukinumab doses by comparing the effects of 150 mg and 300 mg.
Study qualifications include:
More information can be found on the Clinical Trials website.
This study is sponsored by Novartis who has created an informational website for the study. You’ll find additional information, including qualification criteria and participating sites at http://www.asleap.com/.
You can also call (866) 244 - 9578, email firstname.lastname@example.org, or visit the clinical trials study locations page.Learn more about participating in Clinical Studies.
A phase 2/3 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate in a study evaluating the safety and efficacy of Upadacitinib (ABT- 494) - a JAK inhibitor medication taken orally.
The purpose of the trail, titled, “A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis” is to investigate the effectiveness, impact and performance of Upadacitinib by comparing the perceived symptomatic improvements in pain, global assessment, function, and inflammation experienced with Upadacitinib versus a placebo (a mock medication with no therapeutic effects.)
This study is sponsored by AbbVie, who has created a promotional website for the study. You’ll find additional information and a qualification questionnaire at http://clinicalresearchstudy4as.com/.
For location of study centers, you can call (847) 283-8955, email email@example.com or visit the clinical trials study locations page.
The Cedars-Sinai Division of Rheumatology and Center for Outcomes Research and Education are hoping to better understand what matters most to AS patients in selecting an AS medication. This is an online survey and should take about 15 minutes to complete.
This survey is part of a research study conducted by Dr. Brennan Spiegel at Cedars-Sinai Medical Center, and sponsored by Novartis Pharmaceuticals.
Learn more and take the survey here
A phase 3 clinical trial is now recruiting non-radiographic axial Spondyloarthritis (nr-axSpA) patients over the age of 18 to participate in a study of an investigational biologic medication, secukinumab, given by injection.
You may qualify to participate in this study if you:
Additional requirements apply.
If you qualify and agree to be in the study, you will receive the investigational study medication and all study-related care at no cost. Participation is expected to last approximately 24 months.
The purpose of the trial, entitled the “Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis,” is to evaluate the safety, tolerability, and effectiveness of the injected investigational study medication, secukinumab, in helping to decrease the frequency and severity of spondyloarthritis symptoms.
More information can be found at https://clinicaltrials.gov/ct2/show/NCT02696031?cond=NCT02696031&rank=1
This study is sponsored by Novartis Pharmaceuticals. For location of study centers near you, you can contact them at 1-888-669-6682 and ask for NCT02696031.
Learn more about participating in Clinical Studies.
A phase 3 clinical trial is now recruiting axial spondyloarthritis (ankylosing spondylitis) patients over the age of 18 to take part in a three-pronged study. The investigational study medication is an IL-17 inhibitor called Ixekizumab.
Eli Lilly and Company, who is the drug manufacturer and is sponsoring the study, has created a website where you can learn more, and prescreen for each of the studies. See “Find a Lilly Trial.”
The three related studies can also be found through ClinicalTrials.gov, linked below:
Note from SAA: We are delighted to inform you of this study led by Dr. James Rosenbaum, current member of SAA’s Medical and Scientific Advisory Board.
Recent scientific studies have shown that the bacteria and other organisms which normally reside in our gut can have a profound effect on the immune system and inflammatory disease. This study will analyze gut microbe data to determine if there are patterns or certain associations with ankylosing spondylitis or HLA-B27.
Participants will be asked to complete a questionnaire, keep a 2-day food diary and to provide a sample of feces (stool) which can be collected at home and shipped to our research laboratory. An optional sample of saliva may also be provided. There are no costs for participation and all sample packaging and shipping materials are provided. If you choose to be in the study, you will not personally benefit, but may help to benefit patients with ankylosing spondylitis in the future.
For more information, please contact Dr. Rosenbaum’s research team at 503-494-5711 or B27microbiome@ohsu.edu. Thank you!
Oregon Health & Science University
PA: James Rosenbaum, MD
Relationship between HLA B27, disease status and gut microbes (An extension study of “Influence of HLA B27 status and colonoscopy bowel prep on the gut microbiome in conjunction with analysis of the gut microbiome along the gastrointestinal tract”)
Have a spondylitis research study you’d like to let us know about? Contact us at Research@spondylitis.org
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.